REFORM-TAD: Type A Dissection Total Endovascular Reconstruction System for Type A Aortic Dissection

Randomised, open-label trial in Type A Aortic Dissection (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Change in False Lumen Volume of the Distal Aortic Dissection at 12 months and Incidence of major adverse events at 30 days. Planned start Feb 2026; status: not yet recruiting.